Myriad Genetics, a noted biotechnology company based in Washington, USA, recently announced that it had been awarded a patent on 47 different mutations in the BRCA1 gene, abnormalities in which substantially heighten risk of such diseases as breast and ovarian cancer. According to Peter Meldrum, Myriad's president and chief executive officer, the award "establishes a broad and substantial proprietary foundation for the company's products."
We are a voice to you; you have been a support to us. Together we build journalism that is independent, credible and fearless. You can further help us by making a donation. This will mean a lot for our ability to bring you news, perspectives and analysis from the ground so that we can make change together.
Comments are moderated and will be published only after the site moderator’s approval. Please use a genuine email ID and provide your name. Selected comments may also be used in the ‘Letters’ section of the Down To Earth print edition.